Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Randomized Anticoagulation Trial in Opcab (RATIO)

Condition:   Ischemic Heart Disease
Intervention:   Drug: Heparin
Sponsor:   Azienda Ospedaliera di Lecco
Not yet recruiting - verified June 2016

Hospitalization or Out-treatment ManagEment of Patients With Pulmonary Embolism: a Randomized Controlled Trial

Condition:   Pulmonary Embolism
Interventions:   Other: HESTIA;   Other: sPESI
Sponsors:   University Hospital, Angers;   European Georges Pompidou Hospital;   Hospital Universitario Ramon y Cajal;   Leiden University Medical Center;   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Not yet recruiting - verified June 2016

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

Conditions:   Pulmonary Embolism;   Venous Thrombosis
Interventions:   Drug: Enteric Coated Aspirin;   Drug: Warfarin;   Drug: Rivaroxaban
Sponsors:   Medical University of South Carolina;   Patient-Centered Outcomes Research Institute;   University of Maryland;   University of Massachusetts, Worcester;   Brigham and Women's Hospital
Not yet recruiting - verified April 2016

Hokusai VTE Pediatric Study

Conditions:   Venous Thromboembolism;   Pulmonary Embolism
Interventions:   Drug: Edoxaban 60 mg and dosing on mg/kg basis;   Drug: Warfarin dosed at INR level and mg/kg basis;   Drug: Enoxaparin dosed at INR level and mg/kg basis;   Drug: Fondaparinux dosed at INR level and mg/kg basis;   Drug: Edoxaban 45 mg and dosing on mg/kg basis
Sponsor:   Daiichi Sankyo Inc.
Not yet recruiting - verified June 2016

Tumor-educated Platelets in Venous Thromboembolism

Conditions:   Neoplasms;   Venous Thromboembolism
Intervention:  
Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified June 2016

Use of Bemiparine as a Prophylactic Antithrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction

Condition:   Patients Undergoing Microvascular Surgery
Intervention:   Drug: Bemiparine
Sponsors:   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal;   Rovi Pharmaceuticals Laboratories
Recruiting - verified June 2016

Computed Tomography CT Venography During Postpartum Venous Thromboembolism

Condition:   Pulmonary Thromboembolism
Intervention:   Procedure: computed tomography venography
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2016

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban;   Drug: Standard-of-care
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified June 2016

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Condition:   Cancer
Interventions:   Drug: Rivaroxaban;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified June 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified June 2016

PERC Rule to Exclude Pulmonary Embolism in the Emergency Deparment

Condition:   Emergency Patients
Intervention:   Other: PERC based Strategy
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2016

Outpatient Treatment of Low-risk Pulmonary Embolism

Condition:   Pulmonary Embolism
Intervention:   Other: Outpatient Treatment of Pulmonary Embolism
Sponsor:   Intermountain Health Care, Inc.
Recruiting - verified June 2016

Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism

Conditions:   Cancer;   Deep Venous Thrombosis;   Pulmonary Embolism
Intervention:  
Sponsors:   Harry R. Buller;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   VU University Medical Center;   University Medical Center Groningen;   Slotervaart Hospital;   Hôpital Louis Mourier;   Università degli Studi 'G. d'Annunzio' Chieti e Pescara;   Instituto Nacional de Cancerologia de Mexico
Active, not recruiting - verified June 2016

Cook IVC Filter Study

Condition:   Pulmonary Embolism
Intervention:   Device: Günther Tulip® Vena Cava Filter and Cook Celect® Vena Cava Filters
Sponsor:   Cook
Recruiting - verified May 2016

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Conditions:   Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention:   Drug: Rivaroxaban
Sponsors:   Seoul National University Hospital;   Korean Society of Hematology Thrombosis Working Party
Active, not recruiting - verified June 2016

A New Way of Looking at Your Lungs

Conditions:   Respiratory Failure;   Acute Dyspnoea
Interventions:   Other: Computed Tomography;   Other: Thoracic ultrasound;   Other: Spirometry;   Other: Blood tests
Sponsor:   University of Oxford
Recruiting - verified June 2016

Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients

Conditions:   Venous Thromboembolism;   Pulmonary Embolus;   Deep Vein Thrombosis
Intervention:  
Sponsors:   Scripps Health;   Lancaster General Hospital;   University of Florida;   Medical University of South Carolina;   Portland VA Medical Center;   Stanford University;   Johns Hopkins University;   Massachusetts General Hospital;   The University of Texas Health Science Center, Houston;   Medical College of Wisconsin;   Oregon Health and Science University;   Christiana Care Health Services;   San Francisco General Hospital;   University of Utah;   Carolinas Medical Center
Withdrawn - verified June 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2016

"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy

Condition:   Stroke
Interventions:   Biological: rfVIIa;   Other: Standard saline solution
Sponsors:   Dr. David Gladstone;   Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified June 2016